Onsdag 30 Oktober | 09:25:12 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2026-02-19 14:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-16 08:00 Kvartalsrapport 2025-Q2
2025-04-24 - Årsstämma
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-02-19 14:00 Bokslutskommuniké 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning BIOT 1.60 SEK
2024-04-25 - Kvartalsrapport 2024-Q1
2024-04-25 - Årsstämma
2024-02-15 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-17 - Kvartalsrapport 2023-Q2
2023-04-28 - X-dag ordinarie utdelning BIOT 1.60 SEK
2023-04-27 - Kvartalsrapport 2023-Q1
2023-04-27 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning BIOT 1.55 SEK
2022-04-28 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-04-29 - X-dag ordinarie utdelning BIOT 1.50 SEK
2021-04-28 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning BIOT 0.00 SEK
2020-06-04 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-07 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-07-16 - Kvartalsrapport 2019-Q2
2019-04-25 - X-dag ordinarie utdelning BIOT 1.50 SEK
2019-04-24 - Kvartalsrapport 2019-Q1
2019-04-24 - Årsstämma
2019-02-07 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-07-16 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning BIOT 1.40 SEK
2018-04-26 - Kvartalsrapport 2018-Q1
2018-04-26 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-07-18 - Kvartalsrapport 2017-Q2
2017-04-28 - X-dag ordinarie utdelning BIOT 1.25 SEK
2017-04-27 - Årsstämma
2017-02-09 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-11 - Kvartalsrapport 2016-Q2
2016-04-29 - X-dag ordinarie utdelning BIOT 1.00 SEK
2016-04-29 - X-dag bonusutdelning BIOT 0.25
2016-04-28 - Kvartalsrapport 2016-Q1
2016-04-28 - Årsstämma
2016-02-11 - Bokslutskommuniké 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-29 - X-dag ordinarie utdelning BIOT 0.75 SEK
2015-04-28 - Kvartalsrapport 2015-Q1
2015-04-28 - Årsstämma
2015-02-12 - Bokslutskommuniké 2014
2014-10-30 - Kvartalsrapport 2014-Q3
2014-08-14 - Kvartalsrapport 2014-Q2
2014-04-29 - X-dag ordinarie utdelning BIOT 0.60 SEK
2014-04-28 - Kvartalsrapport 2014-Q1
2014-04-28 - Årsstämma
2014-02-13 - Bokslutskommuniké 2013
2013-10-25 - Kvartalsrapport 2013-Q3
2013-08-15 - Kvartalsrapport 2013-Q2
2013-04-26 - X-dag ordinarie utdelning BIOT 0.50 SEK
2013-04-25 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-12 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-08-17 - Kvartalsrapport 2012-Q2
2012-04-27 - X-dag ordinarie utdelning BIOT 0.40 SEK
2012-04-26 - Kvartalsrapport 2012-Q1
2012-04-26 - Årsstämma
2012-02-09 - Bokslutskommuniké 2011
2011-10-26 - Kvartalsrapport 2011-Q3
2011-08-17 - Kvartalsrapport 2011-Q2
2011-04-28 - X-dag ordinarie utdelning BIOT 0.25 SEK
2011-04-27 - Årsstämma
2011-04-27 - Kvartalsrapport 2011-Q1
2011-02-10 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-08-13 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning BIOT 0.20 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-11 - Bokslutskommuniké 2009
2009-10-27 - Kvartalsrapport 2009-Q3
2009-08-14 - Kvartalsrapport 2009-Q2
2009-04-28 - X-dag ordinarie utdelning BIOT 0.20 SEK
2009-04-27 - Kvartalsrapport 2009-Q1
2009-04-27 - Årsstämma

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Biotage är verksamt inom bioteknik. Bolaget tillhandahåller lösningar inom kromatografi, organisk syntes och provberedning. Bolaget har verksamhet på global nivå, främst koncentrerat till Europa, Nordamerika och Asien och en stor del av projekten bedrivs även i samarbete med övriga aktörer inom nämnd marknad. Kunderna återfinns inom vård och omsorg, samt inom livsmedelsindustrin.
2024-04-25 08:00:00

Positive earnings development and a growing proportion of recurring revenues

January-March

  • Net sales amounted to SEK 480 (361) million, an increase of 33.0 percent and an organic decrease of 1.4 percent.
  • EBITDA amounted to SEK 112 (80) million and the EBITDA margin amounted to 23.4 percent (22.3).
  • Adjusted EBITDA amounted to SEK 126 (98) million and adjusted EBITDA margin amounted to 26.2 percent (27.2).
  • Operating profit amounted to SEK 67 (54) million and the operating margin was 13.9 percent (14.8).
  • Profit after tax amounted to SEK 33 (43) million.
  • Earnings per share were SEK 0.42 (0.65) before and after dilution.
  • Cash flow from operating activities increased to SEK 108 (11) million.
  • Adjusted cash flow from operating activities increased to SEK 171 (68) million.
  • Net cash as of March 31 was SEK 426 and SEK 335 million as of December 31.
  • On January 4, it was announced that Tomas Blomqvist will leave his position as CEO and Torben Jørgensen will take over as CEO until a new CEO has been recruited. Kieran Murphy has been appointed Chairman of the Board while Torben Jørgensen is CEO.
  • On February 15, the Board decided on new financial targets. The organic revenue goal is focused on double digit growth percent with a profitability aimed toward the upper twenty percent range (Adjusted EBITDA), both averaging over three years.
  • On February 15, Andrew Kellett was appointed as permanent CFO after having an interim position since September 11, 2023.


Message from the CEO
We delivered very good results for the first quarter with stronger gross margins and adjusted EBITDA. Our new strategy that focusses on being the Global Go-To Separation company, with a well-balanced product portfolio is paying dividends. Our Biologics and Advanced Therapeutics segment accounted for 30% of total revenue during the quarter. We believe this segment will continue to show attractive growth over the next few years.

Revenue in the first quarter was SEK 480 million (361), an increase of 33% compared to the same quarter last year. Adjusted EBITDA was SEK 126 million (98), an increase of 28%. We have seen a recent marked acceleration in customer demand for equipment targeted at the peptide market which we have been unable to fully keep pace with in the first quarter. We are working actively with our partner to ensure additional production capacity is available so that delivery can take place in the required volumes in the coming quarters. Had it not been for this, we would have been able to report positive organic growth rather than the small negative organic growth of -1.4% reported. In Analytical Testing, we continued to experience a good recovery after the decline that followed in the wake of the pandemic, especially in the US.

In the first quarter, our recurring revenue business accounted for 72% of revenue. This has resulted in better predictability and a more even cash flow. In the first quarter of 2024, adjusted cash flow from operating activities amounted to SEK 171 million (68), which was due, among other things, to better management of operating cash flow.

In terms of our different geographical markets, we had very good results in EMEA during the first quarter. We continued to grow organically in this region after a weakening linked to the rapid decline in COVID-19 vaccine production. The Americas also showed organic growth, as well as parts of APAC. Looking at the APAC region as a whole, organic growth failed to materialize as a result of a continued weakening of the market in China.

We are continuously working to improve our performance in terms of production, sales, gross margin, operating costs and operating profit. We have also established a new management system to ensure that we implement decisions in a fast and easy-to-understand way.

We continue to invest in our production facilities in Astrea on the Isle of Man and in research and development of the nanofiber technology platform, which will enable increased capacity and greater yield in applications such as cell and gene therapies. At the same time, we have exciting launches of instruments in several of our other areas ahead of the coming quarters.

Today, Biotage is a company with a better balance between its different product areas, its geographic markets, and its recurring revenues and system.

During this predominantly very positive first quarter of the year, I noticed the incredible hard work and commitment of all our employees. And that gives me a strong belief in the future.

Uppsala, April 25, 2024

Torben Jørgensen
CEO and President